Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 3Phase 4 1Phase 3 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 1HIV Infections 1

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × axicabtagene ciloleucel × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT05077527 2026-04-14

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

AIDS Malignancy Consortium

Phase 1 Recruiting
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, Large B-Cell, Diffuse

NCT05794958 2025-09-23

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Stanford University

Phase 1 Recruiting
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡